On July 26th, ReviR Therapeutics (Xilike Technology) announced the completion of a $30 million series A financing. This round of financing was led by Longpan Investment, and existing shareholders DHVC, Wuyuan Capital, and Yayi Capital continued to invest, with also participation of Crystal Technology and CMT Research Foundation. The investment will be used to further develop ReviR's proprietary AI drug development platform VoyageR, as well as to continue the development of existing pipelines for various neurological disorders, including Huntington's disease and peripheral muscular atrophy (CMT), amyotrophic lateral sclerosis (ALS), and other related clinical stages.
溪砾科技完成3000万美元A轮融资
XiLi Technology has completed a Series A financing of 30 million US dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.